The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial

被引:24
|
作者
Fathi, Mojdeh [1 ]
Alavinejad, Pezhman [2 ]
Haidari, Zahra [3 ]
Amani, Reza [1 ]
机构
[1] Isfahan Univ Med Sci, Food Secur Res Ctr, Sch Nutr & Food Sci, Dept Clin Nutr, Esfahan 8173948763, Iran
[2] Ahvaz Jundishapur Univ Med Sci, Ahvaz Imam Hosp, Alimentary Tract Res Ctr, Ahvaz, Iran
[3] Isfahan Univ Med Sci, Sch Hlth, Dept Biostat & Epidemiol, Esfahan, Iran
基金
美国国家科学基金会;
关键词
Zinc supplementation; Calorie- restriction diet; Non-alcoholic fatty liver; Insulin resistance; Oxidative stress; INSULIN-RESISTANCE; NONDIABETIC PATIENTS; GLYCEMIC CONTROL; LIPID PROFILES; OBESE; DEFICIENCY; STEATOHEPATITIS; PATHOGENESIS; HOMEOSTASIS; ADAPTATION;
D O I
10.1016/j.jtemb.2020.126635
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Evidence indicates the positive effects of zinc on insulin resistance and oxidative stress in metabolic syndrome or diabetes. Non-alcoholic fatty liver disease (NAFLD) is the main hepatic manifestation of insulin resistance and metabolic syndrome. The present study is the first clinical trial that evaluated the effects of zinc supplementation on metabolic and oxidative stress status in overweight/obese patients with NAFLD undergoing calorie- restriction diet. Methods: Fifty six overweight/obese patients with confirmed mild to moderate NAFLD using ultrasonography were randomly allocated to receive 30 mg elemental zinc supplement (n = 29) or placebo (n = 27) along with weight loss diet for 12 weeks. Serum levels of zinc, homeostasis model of assessment-estimated insulin resistance (HOMA-IR), lipid profile, serum superoxide dismutasl (SOD1) and malondialdhyde (MDA) levels were assessed. Results: Serum levels of insulin, SOD1, MDA and HOMA-IR were improved in the treatment group (p < 0.05). Within group comparison showed significant reduction in serum FBS, HbA(1C), TC, LDL-c and TG in the treatment group. Conclusion: Zinc supplementation for three months improved insulin resistance and oxidative stress status in overweight/obese NAFLD patients with no beneficial effects on lipid profiles over weight loss diet.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial
    Zahra Darabi
    Mina Darand
    Zahra Yari
    Mehdi Hedayati
    Amirhosein Faghihi
    Shahram Agah
    Azita Hekmatdoost
    BMC Research Notes, 12
  • [22] The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial
    Mojdeh Fathi
    Pezhman Alavinejad
    Zahra Haidari
    Reza Amani
    Biological Trace Element Research, 2020, 197 : 394 - 404
  • [23] The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial
    Fathi, Mojdeh
    Alavinejad, Pezhman
    Haidari, Zahra
    Amani, Reza
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2020, 197 (02) : 394 - 404
  • [24] The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial
    Abhari, Khadijeh
    Saadati, Saeede
    Yari, Zahra
    Hosseini, Hedayat
    Hedayati, Mehdi
    Abhari, Shahabeddin
    Alavian, Seyyed Moayyed
    Hekmatdoost, Azita
    CLINICAL NUTRITION ESPEN, 2020, 39 : 53 - 60
  • [25] A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
    Saeed Chashmniam
    Seyed Reza Mirhafez
    Maryam Dehabeh
    Mitra Hariri
    Mohsen Azimi Nezhad
    B. Fatemeh Nobakht M. Gh
    European Journal of Clinical Nutrition, 2019, 73 : 1224 - 1235
  • [26] A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
    Chashmniam, Saeed
    Mirhafez, Seyed Reza
    Dehabeh, Maryam
    Hariri, Mitra
    Nezhad, Mohsen Azimi
    Nobakht, B. Fatemeh M. Gh
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2019, 73 (09) : 1224 - 1235
  • [27] Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial
    Dabbaghmanesh, Mohammad Hossein
    Danafar, Farideh
    Eshraghian, Ahad
    Omrani, Gholamhossein Ranjbar
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2018, 12 (04) : 513 - 517
  • [28] Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Chong, Clara Yieh Lin
    Orr, David
    Plank, Lindsay D.
    Vatanen, Tommi
    O'Sullivan, Justin M.
    Murphy, Rinki
    NUTRIENTS, 2020, 12 (04)
  • [29] A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a multispecies probiotic mixture in obese non-alcoholic fatty liver disease
    Ahn, S. B.
    Jun, D. W.
    Saeed, W. K.
    Lee, J. S.
    Chae, Y. J.
    Oh, H. W.
    Jeong, J. Y.
    Kang, H. T.
    Jang, E. C.
    Kang, B. -K.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S592 - S592
  • [30] Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial
    Naeini, Fatemeh
    Namkhah, Zahra
    Tutunchi, Helda
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Yaseri, Mehdi
    Hosseinzadeh-Attar, Mohammad Javad
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (03) : 345 - 353